GSK Investigational Site

Zrifin 70300

0 studies enrolling now · 13 studies all time

What they study most

Asthma, Carcinoma, Renal Cell, Hypertension, Lung Cancer, Non-Small Cell, Neoplasms, Breast, Prostatic Hyperplasia, Pulmonary Disease, Chronic Obstructive, Sepsis, Thrombocytopaenia

Studies at this site

• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer — Completed
• A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) — Stopped early
• GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults — Completed
• GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma — Completed
• Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. — Stopped early
• Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment — Completed
• Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag — Completed
• Brain Metastases In ErbB2-Positive Breast Cancer — Stopped early
• Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer — Completed
• Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer — Completed